New publications have expanded the discussion around the Envisia lung disease test as the firm builds evidence for its recently launched lung cancer nasal swab assay.
Pulmonary Fibrosis Foundation, Celgene Form Biomarker Consortium
The consortium aims to develop assays that can detect biomarkers of pulmonary fibrosis that can be used as early indicators of a treatment's activity.
Robust Overall Stock Market Drives 360Dx Index’s 33 Percent Jump in 2019, Led by Natera, NeoGenomics
Most diagnostics companies saw increases in share prices compared to last year, resulting in a significant jump in the 360Dx Index.
Veracyte Prices $51.3M Public Offering
Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.
The assay correlates shortened telomere lengths in patients of different ages to potential risks for inherited diseases, such as bone marrow failure syndrome and liver cancer.